Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative ...

Cybin is currently advancing its CYB003 program into a critical Phase 3 stage, prompting Canaccord to increase its forecast for research ... a Buy rating on the stock. In terms of development ...

In September 2020, the company listed its shares on the Nasdaq stock exchange ... Founded in 2019, Cybin went public in 2020 on Canada's NEO Exchange through a reverse takeover of Clarmin ...

Fintel reports that on March 13, 2025, Guggenheim initiated coverage of Cybin (NYSEAM:CYBN) with a Buy recommendation. Analyst Price Forecast Suggests ... our exclusive stock picks are powered ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Guggenheim initiated coverage of Cybin (CYBN) with a Buy rating and $35 price target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

it may have a material adverse effect on Cybin’s performance and operations. Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...